Author/Authors :
Fatehi, Shiva Department of Clinical Pharmacy - Tehran University of Medical Sciences, Tehran, Iran , Eshaghi, Hamid Department of Pediatric Infectious Diseases - Children’s Medical Center - Tehran University of Medical Sciences, Tehran, Iran , Sharifzadeh, Meisam Department of Pediatrics - Tehran University of Medical Sciences, Tehran, Iran , Mirrahimi, Bahador Department of Clinical Pharmacy - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Qorbani, Mostafa Non-communicable Diseases Research Center - Alborz University of Medical Sciences, Karaj, Iran , Tanzifi, Parin Department of Pathology - Children’s Medical Center - Tehran University of Medical Sciences, Tehran, Iran , Gholami, Kheirollah Department of Clinical Pharmacy - Tehran University of Medical Sciences, Tehran, Iran , Faghihi, Toktam Department of Clinical Pharmacy - Tehran University of Medical Sciences, Tehran, Iran
Abstract :
Objective: Pharmacokinetic and clinical studies recommend applying loading
dose of colistin for the treatment of severe infections in the critically ill adults.
Pharmacokinetic studies of colistin in children also highlight the need for a
loading dose. However, there are no clinical studies evaluating the effectiveness
of colistin loading dose in children. Methods: In a randomized trial, children
with ventilator-associated pneumonia or central line-associated bloodstream
infection (CLABSI) for whom colistin was initiated, were enrolled. Patients
were randomized into two groups; loading dose and conventional dose treatment
arms. In the conventional treatment arm, colistimethate sodium was initiated
with maintenance dose. In the loading dose group, colistimethate sodium was
commenced with a loading dose of 150,000 international unit/kg, then on the
maintenance dose. Both treatment arms also received meropenem as combination
therapy. Primary outcomes were overall efficacy, clinical improvement and
microbiological cure. Secondary outcomes were colistin-induced nephrotoxicity
and development of resistance. Findings: Thirty children completed this study.
There was a significantly higher overall efficacy in the group received loading
dose (42.9 vs. 6.3%, P = 0.031). There weren’t any significant differences in the
clinical and microbiological endpoints. In the subgroup of children with CLABSI,
results illustrated a trend toward (though statistically nonsignificant) better
clinical cure for patients receiving loading dose. Conclusion: This preliminary
study suggests that colistin loading dose might have some benefits in critically
ill children, specifically in children with CLABSI. Further trials are required
to elucidate colistin best dosing strategy in critically ill children with severe
infections.
Keywords :
Children , clinical efficacy , Colistin , loading dose , safety